MX2009005942A - Anticuerpos recombinantes contra el virus de hepatitis c y metodos para obtener y usar los mismos. - Google Patents

Anticuerpos recombinantes contra el virus de hepatitis c y metodos para obtener y usar los mismos.

Info

Publication number
MX2009005942A
MX2009005942A MX2009005942A MX2009005942A MX2009005942A MX 2009005942 A MX2009005942 A MX 2009005942A MX 2009005942 A MX2009005942 A MX 2009005942A MX 2009005942 A MX2009005942 A MX 2009005942A MX 2009005942 A MX2009005942 A MX 2009005942A
Authority
MX
Mexico
Prior art keywords
recombinant antibodies
hcv
virus
obtaining
methods
Prior art date
Application number
MX2009005942A
Other languages
English (en)
Inventor
Mary S Pinkus
Joan D Tyner
Bailin Tu
James W Scheffel
Michael K White
Jeffrey M Werneke
Robert N Ziemann
David J Hawksworth
Robin A Gutierrez
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2009005942A publication Critical patent/MX2009005942A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se proporcionan anticuerpos recombinantes, incluyendo anticuerpos quiméricos, específicos para proteínas antigénicas de hepatitis C (HCV). Los anticuerpos recombinantes específicamente se unen a regiones diagnósticamente relevantes y de esta manera son adecuados para usarse, por ejemplo, como reactivos de diagnóstico para la detección de HCV, y/o como reactivos de estandarización o reactivos de control positivos en ensayos para la detección de HCV. Los anticuerpos recombinantes también pueden ser utilizados en el tratamiento o prevención de una infección por HCV.
MX2009005942A 2006-12-05 2007-12-05 Anticuerpos recombinantes contra el virus de hepatitis c y metodos para obtener y usar los mismos. MX2009005942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/633,810 US7858752B2 (en) 2006-12-05 2006-12-05 Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
PCT/US2007/086516 WO2008070727A2 (en) 2006-12-05 2007-12-05 Recombinant antibodies against hepatitis c virus and methods of obtaining and using same

Publications (1)

Publication Number Publication Date
MX2009005942A true MX2009005942A (es) 2009-06-17

Family

ID=39476274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005942A MX2009005942A (es) 2006-12-05 2007-12-05 Anticuerpos recombinantes contra el virus de hepatitis c y metodos para obtener y usar los mismos.

Country Status (7)

Country Link
US (2) US7858752B2 (es)
EP (1) EP2099825A4 (es)
JP (1) JP2010511410A (es)
BR (1) BRPI0720154A2 (es)
CA (1) CA2670423A1 (es)
MX (1) MX2009005942A (es)
WO (1) WO2008070727A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144886A2 (en) 2006-06-15 2007-12-21 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
CA2737519A1 (en) * 2008-09-29 2010-04-01 Centocor Ortho Biotech Inc. Anti-cd147 antibodies, methods, and uses
WO2010047830A2 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
CA2780713A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
WO2012006500A2 (en) * 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
FR2984328B1 (fr) * 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
CN103159853A (zh) * 2013-02-23 2013-06-19 浙江家和制药有限公司 全人源抗丙型肝炎病毒核心抗原的基因工程Fab抗体及其制备方法和应用
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
EP3916103A1 (en) 2013-03-14 2021-12-01 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
CA2906421C (en) 2013-03-14 2022-08-16 George J. Dawson Hcv antigen-antibody combination assay and methods and compositions for use therein
CN103254312B (zh) * 2013-03-22 2014-08-13 华北制药集团新药研究开发有限责任公司 一种鼠源单克隆抗体及其制备方法和用途
EP2805972A1 (en) * 2013-05-21 2014-11-26 PAION Deutschland GmbH Novel antibody useful in neurological or neurodegenerative disorders
KR20160119166A (ko) * 2014-02-11 2016-10-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 활성 간염 바이러스 감염의 탐지용 콤보-간염 항원 분석 및 키트
CN107110868B (zh) 2014-10-29 2020-08-21 雅培制药有限公司 采用ns3捕获肽的受试者抗hcv抗体检测测定
EP3274369A4 (en) * 2015-03-27 2018-10-17 University of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors
JP2018518152A (ja) 2015-03-27 2018-07-12 ユニバーシティ オブ サザン カリフォルニア 充実性腫瘍を処置するためのｌｈｒに指向されたｃａｒ ｔ細胞治療
JP2019517813A (ja) * 2016-06-16 2019-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体
WO2019055776A2 (en) 2017-09-14 2019-03-21 Rosser Charles COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING CXCL1 FUNCTION
CN109666649B (zh) * 2018-12-29 2022-03-11 山东莱博生物科技有限公司 稳定高效表达hcv ns3蛋白抗体的工程细胞株及其应用
US11292832B2 (en) 2019-01-28 2022-04-05 Charles J. Rosser Compositions and methods for treatment of diseases involving CXCL1 function
WO2021142413A1 (en) * 2020-01-12 2021-07-15 Vanderbilt University Human antibodies to crimean congo hemorrhagic fever virus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5753430A (en) * 1990-11-07 1998-05-19 Abbott Laboratories Monoclonal antibodies to hepatitis C virus and method for using same
ZA927837B (en) * 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
WO1994011509A2 (en) * 1992-11-16 1994-05-26 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
UA46707C2 (uk) * 1993-05-10 2002-06-17 Чірон Корпорейшн Спосіб типування вірусу гепатиту с (варіанти), набір поліпептидів (варіанти), реагент, що включає комбінацію поліпептидів, які містять типоспецифічні епітопи гепатиту с (варіанти)
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
JPH09191886A (ja) * 1996-01-19 1997-07-29 Asahi Breweries Ltd ヒト高親和性ＩｇＥ受容体に対するヒト型化抗体、半キメラ抗体およびキメラ抗体
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US6030792A (en) * 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
WO2002060954A1 (en) * 2001-01-12 2002-08-08 Karolinska Innovations Ab Materials and methods for treatment of hepatitis c
ITRM20010336A1 (it) * 2001-06-13 2002-12-13 Biostrands S R L Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
US7101683B2 (en) * 2001-06-26 2006-09-05 Abbott Laboratories Methods for the simultaneous detection of HCV antigens and HCV antibodies
CA2450710C (en) * 2001-06-26 2013-11-26 Abbott Laboratories Methods for the simultaneous detection of hcv antigens and hcv antibodies
US7049060B2 (en) 2001-11-05 2006-05-23 Ortho-Clinical Diagnostics, Inc. HCV anti-core monoclonal antibodies
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
CA2498228C (en) * 2002-09-09 2011-03-22 Chiron Corporation Hcv assay
ES2377978T3 (es) * 2004-08-27 2012-04-03 Novartis Vaccines And Diagnostics, Inc. Mutantes de proteínas no estructurales de VHC y usos de los mismos
US7910100B2 (en) * 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
ES2546543T3 (es) * 2005-03-14 2015-09-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticuerpos monoclonales humanos contra los virus Hendra y Nipah
EP1922412A4 (en) * 2005-07-15 2009-07-15 Siemens Healthcare Diagnostics HUMANIZED ANTIBODY CONJUGATES AND CORRESPONDING METHODS, BIOLOGICAL TESTS, REAGENTS AND KITS
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same

Also Published As

Publication number Publication date
WO2008070727A2 (en) 2008-06-12
US7858752B2 (en) 2010-12-28
US20080131912A1 (en) 2008-06-05
US8734793B2 (en) 2014-05-27
CA2670423A1 (en) 2008-06-12
US20110263436A1 (en) 2011-10-27
EP2099825A4 (en) 2010-12-22
WO2008070727A3 (en) 2008-11-13
BRPI0720154A2 (pt) 2014-02-04
EP2099825A2 (en) 2009-09-16
JP2010511410A (ja) 2010-04-15

Similar Documents

Publication Publication Date Title
MX2009005942A (es) Anticuerpos recombinantes contra el virus de hepatitis c y metodos para obtener y usar los mismos.
TW200740840A (en) Diagnostic test kits
WO2008027942A3 (en) Combination hepatitis c virus antigen and antibody detection method
GB2438802A (en) Structure of the hepatitis C virus NS5A protein
TW200512457A (en) Method of diagnosing SARS corona virus infection
WO2006093797A3 (en) Method and kit for detecting porcine reproductive and respiratory syndrome virus
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
IL190744A0 (en) Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
WO2006009880A3 (en) Identifying virally infected and vaccinated organisms
WO2007001737A3 (en) Methods and compositions for detecting herpes simplex virus type 2
EP1855719A4 (en) NEUTRALIZING MONOCLONAL ANTIBODIES TO CORONAVIRES IN CONNECTION WITH HEAVY ACUTE RESPIRATORY SYNDROME
WO2006133911A3 (en) Hepatitis c virus nucleic acid vaccine
MX2007009547A (es) Metodo de deteccion de fiebre porcina clasica.
WO2012006500A3 (en) Monoclonal antibodies against hepatitis c virus core protein
WO2004016586A3 (en) Compositions and methods related to flavivirus envelope protein domain iii antigens
WO2003002749A3 (en) Methods for the simultaneous detection of hcv antigens and hcv antibodies
WO2015196192A3 (en) Methods and compositions relating to dengue virus
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
SG161255A1 (en) Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
TW200801201A (en) Detection of mutations in a gene associated with resistance to viral infection, OAS2 or OAS3
MX2013004069A (es) Antigenos inmunoreactivos de mycoplasma haemofelis e inmunoensayos de diagnostico.
WO2016069762A3 (en) Subject anti-hcv antibody detection assays employing ns3 capture peptides
WO2017062535A3 (en) Borrelia immunoassays and materials therefor
MY166402A (en) Direct detection of unamplified hepatitis c virus rna using unmodified gold nanoparticles

Legal Events

Date Code Title Description
FG Grant or registration